ScoreWhy is Gyre Therapeutics, Inc. ?
1
Positive results in Sep 25
- RAW MATERIAL COST(Y) Fallen by 1.65% (YoY)
- NET SALES(Q) Highest at USD 30.56 MM
- OPERATING PROFIT(Q) Highest at USD 7.58 MM
2
With ROE of 7.38%, it has a expensive valuation with a 8.23 Price to Book Value
- Over the past year, while the stock has generated a return of -22.41%, its profits have fallen by -31.1%
3
Majority shareholders : Mutual Funds
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 17.36% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -22.41% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Gyre Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Gyre Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Gyre Therapeutics, Inc.
-22.41%
-0.26
85.52%
S&P 500
17.36%
0.89
19.55%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
41.49%
EBIT Growth (5y)
17.39%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.95%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
112
Industry P/E
Price to Book Value
8.23
EV to EBIT
75.34
EV to EBITDA
61.51
EV to Capital Employed
18.38
EV to Sales
6.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
24.40%
ROE (Latest)
7.38%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend14What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 1.65% (YoY
NET SALES(Q)
Highest at USD 30.56 MM
OPERATING PROFIT(Q)
Highest at USD 7.58 MM
OPERATING PROFIT MARGIN(Q)
Highest at 24.78 %
PRE-TAX PROFIT(Q)
Highest at USD 7.65 MM
NET PROFIT(Q)
Highest at USD 3.63 MM
EPS(Q)
Highest at USD 0.03
-6What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD 2.03 MM
NET PROFIT(9M)
At USD 4.8 MM has Grown at -28.82%
DEBTORS TURNOVER RATIO(HY)
Lowest at 4.51 times
Here's what is working for Gyre Therapeutics, Inc.
Net Profit
At USD 3.63 MM has Grown at 181.3%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 30.56 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 7.58 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 24.78 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 7.65 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD 7.65 MM has Grown at 84.03%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 3.63 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.03
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by 1.65% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Gyre Therapeutics, Inc.
Operating Cash Flow
Lowest at USD 2.03 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debtors Turnover Ratio
Lowest at 4.51 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
